Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Respiratory indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Asbestos-related disease and mesothelioma risk

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

New severe breathlessness, large unilateral pleural effusion, haemoptysis, hypoxaemia, vena-caval obstruction or uncontrolled chest pain requires urgent assessment. Suspected mesothelioma or lung cancer should enter the current NICE suspected-cancer pathway; a known asbestos history must accelerate attention, not provide a benign explanation. If asbestos-containing material is encountered, do not sample or disturb it clinically—direct the person to competent local or HSE advice.

Overview

Distinguish benign pleural markers, asbestosis and asbestos-related malignancy, take a defensible exposure history and route suspicious symptoms urgently without overstating screening benefits.

Asbestos fibres were widely used in insulation, shipbuilding, construction, power generation, railways and many industrial products. Exposure can be direct, bystander or para-occupational through contaminated clothing. The clinical spectrum separates pleural from parenchymal disease. Plaques mark exposure; diffuse pleural thickening can restrict the chest and cause breathlessness; rounded atelectasis is a benign folded-lung appearance that may mimic a mass; asbestosis produces basal subpleural fibrosis; malignancy includes lung cancer and mesothelioma.

Risk assessment is qualitative in ordinary clinical care. Exposure intensity, fibre type, duration and latency matter, but recollection is incomplete and there is no single blood test that proves past exposure. Smoking is not a cause of mesothelioma but amplifies asbestos-associated lung-cancer risk. Conversely, mesothelioma can occur without a clear remembered occupational episode, so lack of a history cannot close investigation of suspicious pleural disease.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RespiratoryOriginal SBA

Meaning of pleural plaques

An asymptomatic retired electrician has incidental calcified pleural plaques and normal lung function. Which explanation is most accurate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Respiratory topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • HSE asbestos health dangersCurrent UK regulator summary of mesothelioma, lung cancer, asbestosis and pleural thickening risks.
  • NICE suspected cancer recommendationsCurrent referral criteria for suspected mesothelioma and lung cancer.
  • BTS malignant pleural mesothelioma guidelineUK specialty recommendations for imaging, tissue diagnosis, staging and patient support.
  • GOV.UK industrial injuries eligibilityCurrent statutory signposting for listed asbestos-related diseases; eligibility decisions remain with the scheme.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
There is no medicine that removes fibres or reverses asbestosis. Care focuses on prevention of further exposure, smoking cessation, vaccination, pulmonary rehabilitation, oxygen assessment and management of comorbidity. New pleural symptoms are investigated promptly rather than placed into unsupported routine screening. Suspected malignant pleural mesothelioma is managed by a specialist cancer MDT using imaging and adequate tissue; treatment options and commissioning evolve and must follow current oncology guidance.

Key points

  • Asbestos exposure can cause pleural plaques, benign pleural effusion, diffuse pleural thickening, rounded atelectasis, asbestosis, lung cancer and malignant mesothelioma.
  • Disease typically follows a long latency, so relevant work may have occurred decades before retirement, migration or symptom onset.
  • Pleural plaques are markers of previous exposure and are usually asymptomatic; they are not themselves malignant or a precursor that transforms into mesothelioma.
  • Asbestosis is diffuse pulmonary fibrosis caused by substantial cumulative asbestos exposure and must be differentiated from IPF and other fibrotic ILDs.
  • Mesothelioma commonly presents with progressive unilateral chest pain, breathlessness, pleural effusion or pleural thickening and nodularity.
  • A normal chest radiograph cannot rule out early pleural malignancy in a symptomatic person, and previous normal imaging does not provide lasting reassurance.
  • Smoking and asbestos exposure together greatly increase lung-cancer risk; stopping smoking is a valuable intervention even long after occupational exposure ended.
  • Do not use a plaque burden to calculate an individual's mesothelioma future or promise that routine CT surveillance will prevent asbestos-related cancer.
  • Document employers, dates, trades, tasks, materials, co-workers, lagging or insulation work and respiratory protection rather than recording only 'builder'.

Aetiology

01

Occupational asbestos exposure

Construction, shipbuilding, insulation, engineering and maintenance work historically generated inhalable fibres, often decades before respiratory or pleural disease becomes apparent.

02

Secondary environmental exposure

Household contact with contaminated work clothing and residence near asbestos industries can create meaningful exposure despite no direct trade history.

03

Fibre burden and latency

Risk rises with cumulative exposure for asbestosis and lung cancer, while mesothelioma can follow lower exposure after a long latent interval.

04

Smoking interaction

Smoking strongly multiplies lung-cancer risk in asbestos-exposed people but does not account for pleural plaques or the main mesothelioma association.

Pathophysiology

  1. 1
    Fibre deposition

    Durable inhaled fibres reach distal airways, alveoli and pleura, where clearance is incomplete and residence is prolonged.

  2. 2
    Chronic inflammation

    Macrophage activation and reactive mediators stimulate fibroblasts, producing diffuse interstitial fibrosis in sufficiently exposed susceptible lungs.

  3. 3
    Pleural response

    Fibres reaching the pleura promote localised collagen deposition as plaques or more diffuse pleural thickening, which may restrict chest mechanics.

  4. 4
    Carcinogenesis

    Persistent fibre-related oxidative and chromosomal injury increases malignant transformation risk in mesothelial and bronchial epithelial cells over decades.

Clinical features and red flags

Pleural plaques

Often incidental, bilateral focal pleural thickening or calcification follows the parietal pleura and diaphragmatic domes. Plaques usually do not explain marked breathlessness or restrictive physiology.

Diffuse pleural thickening

More extensive visceral pleural fibrosis can obliterate the costophrenic angle, encase lung and reduce volumes, sometimes after a benign asbestos-related pleural effusion.

Asbestosis

Progressive exertional breathlessness, fine basal crackles, restrictive physiology and reduced TLCO accompany basal subpleural fibrosis after sufficient cumulative exposure, often with pleural markers.

Possible pleural mesotheliomaRed flag

Unilateral progressive chest pain, breathlessness, recurrent exudative effusion, nodular pleural thickening or loss of hemithoracic volume warrants urgent cancer-pathway referral.

Possible lung cancerRed flag

Haemoptysis, unexplained weight loss, persistent cough, focal mass, lobar collapse, supraclavicular node or clubbing requires the current suspected-lung-cancer pathway whether or not asbestosis is present.

Acute pleural compromiseRed flag

A large effusion causing hypoxaemia, severe dyspnoea or mediastinal compromise needs same-day pleural assessment and symptom relief with appropriately planned diagnostic sampling.

Investigations

  1. 01
    Lifetime occupational and environmental historyFirst step
    Why
    Establish plausible exposure, latency and potential ongoing risk.
    Interpretation and limitations
    Ask about insulation, lagging, demolition, ship or rail work, boiler rooms, asbestos cement, building maintenance and family clothing exposure. Job title alone underestimates contact.
  2. 02
    Chest radiograph
    Why
    Identify pleural, interstitial or malignant warning findings.
    Interpretation and limitations
    Plaques, costophrenic blunting, basal reticulation, effusion, volume loss or a mass guide next steps. A normal film does not exclude early mesothelioma in a symptomatic person.
  3. 03
    Contrast CT chest or HRCT
    Why
    Characterise suspicious pleura, fibrosis and alternative disease.
    Interpretation and limitations
    Contrast technique is selected for pleural malignancy; HRCT characterises asbestosis. Nodular circumferential or mediastinal pleural thickening is concerning, while plaques alone are benign exposure markers.
  4. 04
    Spirometry, lung volumes and TLCO
    Why
    Measure functional impact and provide a follow-up baseline.
    Interpretation and limitations
    Restriction supports physiologically important pleural or parenchymal disease, but smoking-related obstruction and emphysema may coexist. Plaques alone should not be blamed for substantial impairment without another cause.

Differential diagnosis

01

Idiopathic pulmonary fibrosis

A usual interstitial pneumonia pattern can resemble asbestosis, but a credible cumulative exposure and pleural markers support asbestos attribution.

02

Benign pleural plaque

Well-demarcated often calcified parietal plaques mark prior exposure but do not themselves indicate mesothelioma or usually cause major breathlessness.

03

Metastatic pleural malignancy

Pleural nodularity and effusion may arise from lung, breast or other cancer; adequate tissue and immunohistochemistry distinguish origin.

04

Other occupational fibrosis

Silica, coal and mixed-dust exposure produce different radiological distributions and occupational patterns that a detailed job history helps separate.

Management

01Exposure consultationSeparate risk marker from diseaseFirst stepA patient reports asbestos contact or incidental plaques are found.+
  1. 1Take a task-based lifetime exposure and smoking history, assess respiratory symptoms and explain that plaques confirm exposure but do not themselves become cancer.
  2. 2For asymptomatic plaques, avoid attributing unrelated breathlessness or arranging unsupported serial CT; address smoking cessation and provide symptom safety-netting.
  3. 3When breathlessness or physiological abnormality exists, investigate COPD, cardiac disease, diffuse pleural thickening, asbestosis and other ILD rather than assuming plaques are causal.
  4. 4Discuss occupational documentation and signpost benefits or independent legal advice where appropriate, clearly separating clinical opinion from eligibility decisions.
02Suspected cancerFast-track suspicious pleural disease

Complications

01

Progressive pulmonary fibrosis

Asbestosis can reduce lung compliance and gas transfer, causing exertional hypoxaemia, respiratory failure and pulmonary hypertension.

02

Malignant mesothelioma

Pleural mesothelial cancer may present with chest pain, recurrent effusion and progressive pleural encasement many years after exposure.

03

Lung cancer

Asbestos exposure independently increases bronchogenic cancer risk, with a markedly greater combined risk in people who also smoke.

04

Restrictive pleural disease

Diffuse pleural thickening can tether lung and chest wall, reducing volumes and causing persistent breathlessness without parenchymal asbestosis.

Monitoring and follow-up

  • For established asbestosis or diffuse pleural thickening, track symptoms, activity, oxygen saturation, FVC and TLCO at respiratory intervals matched to severity.
  • Investigate new unilateral chest pain, effusion, haemoptysis, weight loss or focal radiographic change immediately rather than awaiting a routine surveillance appointment.
  • Reassess exertional oxygenation when walking capacity declines and route oxygen through the local commissioned assessment service.
  • Review smoking status and offer evidence-based cessation support repeatedly without suggesting that past exposure makes quitting futile.
  • Document exposure details and copies of diagnostic reports that may assist occupational-health or benefits assessment, with patient consent.
  • After mesothelioma diagnosis, monitor symptoms, pleural fluid recurrence, nutrition and treatment toxicity through the cancer MDT and specialist nurse plan.

Special situations

Plaques are not premalignant

They demonstrate previous asbestos exposure but do not transform into mesothelioma. Their presence informs risk history, while new symptoms still need their own diagnosis.

Absence of plaques does not clear exposure

Asbestos-related malignancy can occur without visible plaques, and a plausible occupational history remains relevant even when the pleura looked normal previously.

Smoking changes lung-cancer risk

Tobacco does not explain mesothelioma, but it compounds asbestos-associated lung cancer. Smoking cessation remains one of the most useful modifiable interventions.

Rounded atelectasis can mimic tumour

A folded peripheral mass adjacent to pleural disease may show a comet-tail appearance, but interval change or atypical features still require radiological and MDT judgement.

Diagnosis and compensation differ

A clinician documents exposure and disease; statutory benefit and civil claims apply separate legal tests. Signposting is appropriate, while guaranteeing an outcome is not.

Common pitfalls

  1. 01

    Telling an asymptomatic patient that pleural plaques are an early cancer requiring chemotherapy.

  2. 02

    Reassuring a symptomatic asbestos-exposed patient solely because a previous chest radiograph was normal.

  3. 03

    Calling every basal fibrotic HRCT asbestosis without checking exposure intensity and alternative ILD causes.

  4. 04

    Assuming negative pleural-fluid cytology excludes mesothelioma despite suspicious CT and recurrent unilateral effusion.

  5. 05

    Promising that annual CT surveillance will prevent mesothelioma when no such universal UK programme exists.

  6. 06

    Giving detailed legal eligibility advice beyond competence instead of documenting facts and signposting expert services.

  • Discuss Industrial Injuries Disablement Benefit, relevant lump-sum schemes and independent legal or welfare advice without making eligibility promises outside the responsible service.
    • 05
    Pleural ultrasound and fluid sampling
    Why
    Manage an effusion safely and obtain diagnostic material.
    Interpretation and limitations
    Ultrasound guides aspiration. Cytology may be insufficient for mesothelioma; a negative sample does not end investigation when imaging and symptoms remain suspicious.
  • 06
    Image-guided or thoracoscopic pleural biopsy
    Why
    Secure adequate tissue for mesothelioma diagnosis and molecular pathology.
    Interpretation and limitations
    The pleural MDT chooses the safest high-yield route, considering fluid control and future intervention. Avoid repeated low-yield procedures that delay definitive tissue.
  • 07
    Cancer staging and fitness assessment
    Why
    Define extent and guide specialist treatment options.
    Interpretation and limitations
    CT, PET-CT or other tests are selected after MDT review; imaging cannot replace histology in most cases. Performance status, lung function and patient priorities influence treatment.
    • New unilateral effusion, pleural thickening, progressive pain or other mesothelioma features appear.
    +
    1. 1Refer using the current suspected-cancer pathway and arrange contrast CT through the local lung or pleural service; do not wait for a compensation history to be complete.
    2. 2Use ultrasound-guided fluid sampling for symptomatic effusion, recognising that negative cytology cannot exclude mesothelioma.
    3. 3Discuss at the pleural cancer MDT and obtain adequate image-guided or thoracoscopic biopsy when clinically appropriate, coordinating diagnosis with fluid control.
    4. 4Provide a lung cancer nurse contact, symptom relief and clear communication while oncology determines staging and treatment using current NICE and local guidance.
    03Asbestosis careManage irreversible fibrotic diseaseExposure-linked diffuse pulmonary fibrosis is established.+
    1. 1Confirm that exposure intensity, latency and HRCT pattern fit and that IPF, CTD-ILD, hypersensitivity pneumonitis and drug causes have been considered at respiratory or ILD review.
    2. 2Measure baseline physiology and exercise oxygenation, offer smoking cessation, vaccination and pulmonary rehabilitation, and assess oxygen when hypoxaemia is present.
    3. 3Follow symptoms and function according to severity, investigating disproportionate change for cancer, infection, pulmonary hypertension, cardiac disease or embolism.
    4. 4Address breathlessness and future-care priorities proactively; no antifibrotic or immunosuppressive medicine should be assumed effective outside specialist evidence and commissioning pathways.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Treats hypoxaemia from advanced asbestosis, pleural compromise or another acute respiratory complication while definitive assessment proceeds.

    Controlled oxygen

    In acute hypoxaemia titrate to 94–98% for most adults or 88–92% when hypercapnic respiratory failure risk exists, pending blood gases and any patient-specific target.

    Oxygen does not reverse fibrosis or treat breathlessness in a normally oxygenated patient. Ambulatory and long-term oxygen require formal assessment; a rising requirement should trigger investigation of malignancy and other acute causes.

    Supports smoking cessation to reduce lung-cancer, cardiovascular and obstructive-lung-disease risk after asbestos exposure.

    Nicotine replacement therapy

    Choose a licensed patch, gum, lozenge, inhalator or combination regimen according to tobacco dependence and current local stop-smoking formulary, with behavioural support and product-specific instructions.

    Review recent acute cardiovascular illness, pregnancy, skin reaction and correct product use, though continuing smoking is usually more harmful. Do not imply cessation removes established asbestos-related mesothelioma risk.